Advertisement

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Welcome and Introduction to Vi3C

David A. Hyman, MD, JD, on Inclusive Shared Savings

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Advertisement

Advertisement




Feb
11
Today In Oncology
A New Risk Model for Esophagectomy Draws on the STS National Database
Olaparib in Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA
Ultra–Low-Dose Immunotherapy in Relapsed or Refractory Solid Tumors
ASCO and Conexiant Launch ASCO AI in Oncology
Self-Acupressure May Ease Fatigue in Ovarian Cancer Survivors
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo